ReviewRheumatology international2024
Diagnosis, monitoring, and management of axial spondyloarthritis.
Review in Rheumatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Lower HLA-B27 positivity and heterogeneous late-onset case proportions across axial spondyloarthritis cohorts: a systematic review and meta-analysis.Rheumatology international · 2026Pooled it
- Cost-utility of long-term exercise therapy in people with axial spondyloarthritis and severe functional limitations: a randomized, controlled trial.Rheumatology international · 2026Trial
- Impact of the digital health application ViViRA on spinal mobility, physical function, quality of life and pain perception in spondyloarthritides patients: a randomized controlled trial.Arthritis research & therapy · 2024Trial
- Performance of inflammatory back pain criteria in axial psoriatic arthritis compared with non-psoriatic axial spondyloarthritis and chronic low back pain: a cross-sectional study.Rheumatology international · 2026Article
- Ankylosing spondylitis following chronic brucellosis: a causal association or separate pathology? A case-based review.Rheumatology international · 2026Review
- Efficacy of Ixekizumab in Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level: A Pooled Analysis of Phase III Trials.Rheumatology and therapy · 2026Article
- Disease-related and psychosocial factors associated with difficult-to-manage and treatment-refractory axial spondyloarthritis: insights from the Greek AxSpA Registry.Rheumatology international · 2026Article
- Treatment Adherence, Psychosocial Factors, and Clinical Outcomes in Repeatedly Hospitalized Patients with Rheumatoid Arthritis and Ankylosing Spondylitis: An Exploratory Mid-Term Longitudinal Mixed-Effects Study.Medical sciences (Basel, Switzerland) · 2026Observational
- Exercise adherence, perceived exercise benefits and barriers, and spinal mobility in ankylosing spondylitis: a cross-sectional study.Rheumatology international · 2026Observational
- Associations Between Depression and Reduced Quality of Life in Women with Non-Radiographic Axial Spondyloarthritis: A Cross-Sectional Study.Biomedicines · 2026Article
- Evidence on physical activity-sleep associations in axial spondyloarthritis: a scoping review of current findings.Rheumatology international · 2026Article
- Age at Onset Impact on Clinical Profile, Treatment, and Real-Life Perception in Spondyloarthritis Patients, Enhancing a Personalized Approach: A Monocentric Cohort Analysis.Journal of personalized medicine · 2026Article
- Ambiguities in the effect of physical activity on bone remodelling in spondyloarthritis.Reumatologia · 2026Review
- Representation of underserved communities in non-pharmacological axial spondyloarthritis trials: a scoping review protocol.Rheumatology advances in practice · 2026Article
- Imaging pathways in spondyloarthritis: integrating radiography, ultrasonography, magnetic resonance imaging, low-dose computed tomography, and artificial intelligence methods : Radiology and AI in SpA.Rheumatology international · 2025Review
- Integrative mass spectrometry-driven multi-omics and single cell technologies in ankylosing spondylitis: insights into pathogenesis, biomarker discovery, and precision medicine.Journal of translational autoimmunity · 2025Review
- A retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab.BMC rheumatology · 2025Article
- The impact of nurse-led disease management education on outcomes of patients with ankylosing spondylitis: a randomised controlled trial.Journal of research in nursing : JRN · 2025Article
- Profile of patients with axial spondyloarthritis in Latin America: first report from the ESPALDA-PANLAR registry.Rheumatology international · 2025Article
- HLA-B27 Status in Rheumatic Diseases: Clinical and Immunological Differences Between Positive and Negative Patients-A Comparative Study.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Axial spondyloarthritis (axSpA) is a chronic condition predominantly affecting the spine and sacroiliac joints. This article provides an in-depth overview of the current approaches to diagnosing, monitoring, and managing axSpA, including insights into developing terminology and diagnostic difficulties. A substantial portion of the debate focuses on the challenging diagnostic procedure, noting the difficulty of detecting axSpA early, particularly before the appearance of radiologic structural changes. Despite normal laboratory parameters, more than half of axSpA patients experience symptoms. X-ray and magnetic resonance imaging (MRI) are essential for evaluating structural damage and inflammation. MRI can be beneficial when there is no visible structural damage on X-ray as it can help unravel bone marrow edema (BME) as a sign of ongoing inflammation. The management covers both non-pharmacological and pharmacological approaches. Lifestyle modifications, physical activity, and patient education are essential components of the management. Pharmacological therapy, including nonsteroidal anti-inflammatory drugs (NSAIDs) and biologic disease-modifying anti-rheumatic drugs (bDMARDs), are explored, emphasizing individualized treatment. To effectively manage axSpA, a comprehensive and well-coordinated approach is necessary, emphasizing the significance of a multidisciplinary team. Telehealth applications play a growing role in axSpA management, notably in reducing diagnostic delays and facilitating remote monitoring. In conclusion, this article underlines diagnostic complexities and emphasizes the changing strategy of axSpA treatment. The nuanced understanding offered here is designed to guide clinicians, researchers, and healthcare providers toward a more comprehensive approach to axSpA diagnosis and care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.